SecBot SecBot
8-K ·Filed Aug 6, 2026

REPL

Replimune Group, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed3mo ago SEC0001104659-26-092246
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

FDA approval removes binary pipeline risk and unlocks first commercial revenue. Watch for early prescription uptake and reimbursement decisions (payer coverage reaching ~80% of lives). Next catalysts: IGNYTE-3 interim OS data and RP2 uveal melanoma/HCC/BTC pipeline readouts. The accelerated approval label includes confirmatory trial risk, a negative IGNYTE-3 result could jeopardize continued approval.

DirectionBullish
Confidencehigh
Horizonweeks

TUDRIQEV

● Neutral Named in this 8-K
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already approved and commercially available in the U.S. since October 2026.
Next catalyst
None dated

What to watchTUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$12.06
T+0 close · Aug 6, 2026 · via day close
Latest settled
+56.97%
T+60 · $18.93
Vs SPY
+59.10%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 7 $12.06entry
  2. T+1 · 3mo ago +13.35%α +13.38% · $13.67
  3. T+5 · 3mo ago +24.13%α +23.73% · $14.97
  4. T+20 · 2mo ago +24.71%α +25.11% · $15.04
  5. T+60 · 15d ago +56.97%α +59.10% · $18.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Replimune announced on August 6, 2026 that the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who progressed on a PD-1-based regimen. Continued approval is contingent on verification of clinical benefit in the ongoing confirmatory Phase 3 trial IGNYTE-3. This is Replimune's first approved product, validating its RPx platform and opening a ~10,000 addressable-patient market in the U.S.

Key Facts

  • FDA granted accelerated approval for TUDRIQEV (RP1) + nivolumab in advanced melanoma after anti-PD-1 progression
  • IGNYTE trial (n=91 efficacy-evaluable): ORR 24.2%, median DOR 14.1 months, 86.1% of responders had DOR >6 months
  • No grade 4/5 common adverse events; most adverse reactions were grade 1-2 and transient
  • Broad label: no prior BRAF requirement, treat superficial/deep/visceral lesions, retreatment allowed
  • Confirmatory Phase 3 trial IGNYTE-3 (N~400, PFS/OS) is ongoing
  • First revenue expected in next 6 months; TUDRIQEV expected to ship in ~60 days
  • Company has 63,000 sq ft U.S. manufacturing facility; cost of treatment in line with comparable advanced melanoma therapies

Financial Impact

Replimune transitions from pre-revenue biotech to commercial stage; initial revenue expected within 6 months. No revenue or EPS figures provided in filing.

revenuecash_flow

Risk Factors

  • Accelerated approval is contingent on positive confirmatory Phase 3 IGNYTE-3 data (OS primary endpoint)
  • First commercial product, limited experience in sales, manufacturing scale-up, and market access
  • Competition from approved therapies in advanced melanoma (Opdualag, TIL, BRAF/MEK, chemo)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
57% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-092246
Document: tm2622487d1_8k.htm0001104659-26-092246
Document: tm2622487d1_ex99-1.htm0001104659-26-092246
Document: 0001104659-26-092246-index-headers.html0001104659-26-092246
Document: 0001104659-26-092246-index.html0001104659-26-092246
Document: 0001104659-26-092246.txt0001104659-26-092246

Track record

32 reports on REPL

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
  2. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
  5. Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
  6. Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
  7. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
  8. Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
  9. Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
  10. Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
Showing 10 of 32

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 7, 2026